Evogene Ltd. (EVGN)
NASDAQ: EVGN · IEX Real-Time Price · USD
0.662
-0.004 (-0.53%)
Nov 30, 2023, 10:39 AM EST - Market open
Evogene Revenue
Evogene had revenue of $5.72M in the twelve months ending September 30, 2023, with 331.52% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $3.77M with 708.37% year-over-year growth. In the year 2022, Evogene had annual revenue of $1.68M with 80.11% growth.
Revenue (ttm)
$5.72M
Revenue Growth
+331.52%
P/S Ratio
5.70
Revenue / Employee
$41,766
Employees
137
Market Cap
32.61M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 1.68M | 745.00K | 80.11% |
Dec 31, 2021 | 930.00K | -110.00K | -10.58% |
Dec 31, 2020 | 1.04M | 287.00K | 38.11% |
Dec 31, 2019 | 753.00K | -994.00K | -56.90% |
Dec 31, 2018 | 1.75M | -1.63M | -48.33% |
Dec 31, 2017 | 3.38M | -3.16M | -48.30% |
Dec 31, 2016 | 6.54M | -4.59M | -41.23% |
Dec 31, 2015 | 11.13M | -3.38M | -23.31% |
Dec 31, 2014 | 14.51M | -3.07M | -17.46% |
Dec 31, 2013 | 17.58M | 509.00K | 2.98% |
Dec 31, 2012 | 17.07M | 2.17M | 14.57% |
Dec 31, 2011 | 14.90M | 2.34M | 18.61% |
Dec 31, 2010 | 12.56M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Centogene | 55.72M |
electroCore | 13.40M |
Bolt Biotherapeutics | 7.20M |
BeyondSpring | 1.35M |
Gain Therapeutics | 55.18K |
EVGN News
- 2 days ago - Lavie Bio Announces Expansion of its Bio-Inoculant Product for Spring Wheat, Yalos™, to Durum and Barley - PRNewsWire
- 15 days ago - Evogene Reports Third Quarter 2023 Financial Results - PRNewsWire
- 22 days ago - Lavie Bio Reports Advancement in Bio-Fungicide Program Against Downy Mildew with 2023 Field Trial Results - PRNewsWire
- 4 weeks ago - Evogene Schedules Third Quarter 2023 Financial Results Release & Conference Call for November 15, 2023 - PRNewsWire
- 4 weeks ago - Colors Farm, Evogene and Ben-Gurion University Collaborate to Establish Crustacean Gene Editing Technology - PRNewsWire
- 6 weeks ago - Evogene Provides Operational Update Amidst Current Security Situation in Israel - PRNewsWire
- 2 months ago - Casterra Delivers First Shipment of Castor Seeds to Africa - PRNewsWire
- 3 months ago - Evogene Reports Second Quarter 2023 Financial Results - PRNewsWire